Ceralifimod

Drug Profile

Ceralifimod

Alternative Names: MSC-2430913A; ONO-4641; S1P agonist - Ono Pharmaceutical

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Ono Pharmaceutical
  • Class Azetidines; Carboxylic acids; Naphthalenes; Small molecules
  • Mechanism of Action Sphingosine 1 phosphate receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Multiple sclerosis

Most Recent Events

  • 27 Dec 2014 Ono terminates a phase III trial in Multiple Sclerosis in Austria, Belgium, Estonia, Germany, Greece, Hungary, Latvia, Portugal and Spain (EudraCT2013-002351-15; EudraCT2013-003126-83)
  • 19 Jun 2014 Merck terminates its licence for ceralifimod
  • 16 Apr 2014 Phase-III clinical trials in Multiple sclerosis in Belgium (PO) (EudraCT2013-003126-83)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top